Drugs / CUE-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03978689 | Jul 2019 → Jan 2026 | human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma | Cue Biopharma | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07172256 | May 2026 → Feb 2031 expected | oropharynx squamous cell carcinoma | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT04852328 | Dec 2021 → Oct 2027 expected | oropharynx squamous cell carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUE-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172256 ↗ |
| Modality | Protein / enzyme biologic | “CUE-101, a novel therapeutic fusion protein” PMID 31964784 ↗ Jan 2020 |
| Route | Intravenous | “Intravenous administration of CUE-101 induced selective expansion of HPV16 E7” PMID 31964784 ↗ Jan 2020 |